Citadel Advisors’s Anika Therapeutics ANIK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $755K | Buy |
52,062
+4,996
| +11% | +$58K | ﹤0.01% | 8340 |
|
|
2025
Q4 | $452K | Buy |
47,066
+27,683
| +143% | +$265K | ﹤0.01% | 9273 |
|
|
2025
Q3 | $182K | Sell |
19,383
-8,870
| -31% | -$84.7K | ﹤0.01% | 11354 |
|
|
2025
Q2 | $299K | Sell |
28,253
-40,183
| -59% | -$507K | ﹤0.01% | 9835 |
|
|
2025
Q1 | $1.03M | Sell |
68,436
-3,099
| -4% | -$51.6K | ﹤0.01% | 6892 |
|
|
2024
Q4 | $1.18M | Buy |
71,535
+29,465
| +70% | +$581K | ﹤0.01% | 6683 |
|
|
2024
Q3 | $1.04M | Sell |
42,070
-47,063
| -53% | -$1.22M | ﹤0.01% | 6796 |
|
|
2024
Q2 | $2.26M | Buy |
89,133
+48,931
| +122% | +$1.27M | ﹤0.01% | 5089 |
|
|
2024
Q1 | $1.02M | Sell |
40,202
-149,248
| -79% | -$3.61M | ﹤0.01% | 6873 |
|
|
2023
Q4 | $4.29M | Buy |
189,450
+61,781
| +48% | +$1.28M | ﹤0.01% | 4028 |
|
|
2023
Q3 | $2.38M | Buy |
127,669
+104,975
| +463% | +$2.18M | ﹤0.01% | 4905 |
|
|
2023
Q2 | $590K | Buy |
22,694
+15,185
| +202% | +$406K | ﹤0.01% | 7571 |
|
|
2023
Q1 | $216K | Sell |
7,509
-72,254
| -91% | -$2.15M | ﹤0.01% | 10052 |
|
|
2022
Q4 | $2.36M | Buy |
79,763
+65,256
| +450% | +$1.86M | ﹤0.01% | 5166 |
|
|
2022
Q3 | $345K | Buy |
+14,507
| New | +$334K | ﹤0.01% | 9266 |
|
|
2021
Q4 | – | Sell |
-29,985
| Closed | -$1.28M | – | 13733 |
|
|
2021
Q3 | $1.28M | Sell |
29,985
-20,299
| -40% | -$836K | ﹤0.01% | 7506 |
|
|
2021
Q2 | $2.18M | Buy |
50,284
+30,300
| +152% | +$1.29M | ﹤0.01% | 6385 |
|
|
2021
Q1 | $815K | Sell |
19,984
-2,400
| -11% | -$91K | ﹤0.01% | 8604 |
|
|
2020
Q4 | $1.01M | Sell |
22,384
-29,781
| -57% | -$1.13M | ﹤0.01% | 6768 |
|
|
2020
Q3 | $1.85M | Buy |
52,165
+17,685
| +51% | +$639K | ﹤0.01% | 4858 |
|
|
2020
Q2 | $1.3M | Sell |
34,480
-56,282
| -62% | -$1.85M | ﹤0.01% | 5344 |
|
|
2020
Q1 | $2.62M | Sell |
90,762
-22,876
| -20% | -$925K | ﹤0.01% | 3690 |
|
|
2019
Q4 | $5.89M | Sell |
113,638
-14,893
| -12% | -$865K | ﹤0.01% | 2887 |
|
|
2019
Q3 | $7.05M | Buy |
128,531
+18,354
| +17% | +$942K | ﹤0.01% | 2656 |
|
|
2019
Q2 | $4.48M | Sell |
110,177
-50,082
| -31% | -$1.83M | ﹤0.01% | 3259 |
|
|
2019
Q1 | $4.85M | Buy |
160,259
+69,050
| +76% | +$2.36M | ﹤0.01% | 3047 |
|
|
2018
Q4 | $3.06M | Sell |
91,209
-3,287
| -3% | -$119K | ﹤0.01% | 3488 |
|
|
2018
Q3 | $3.99M | Sell |
94,496
-64,013
| -40% | -$2.53M | ﹤0.01% | 3297 |
|
|
2018
Q2 | $5.07M | Buy |
158,509
+111,664
| +238% | +$4.6M | ﹤0.01% | 2753 |
|
|
2018
Q1 | $2.33M | Buy |
46,845
+11,986
| +34% | +$677K | ﹤0.01% | 3499 |
|
|
2017
Q4 | $1.88M | Buy |
34,859
+10,550
| +43% | +$584K | ﹤0.01% | 3726 |
|
|
2017
Q3 | $1.41M | Sell |
24,309
-9,879
| -29% | -$516K | ﹤0.01% | 3844 |
|
|
2017
Q2 | $1.69M | Buy |
34,188
+1,713
| +5% | +$78.9K | ﹤0.01% | 3395 |
|
|
2017
Q1 | $1.41M | Sell |
32,475
-8,158
| -20% | -$389K | ﹤0.01% | 3508 |
|
|
2016
Q4 | $1.99M | Buy |
40,633
+20,170
| +99% | +$933K | ﹤0.01% | 2958 |
|
|
2016
Q3 | $980K | Buy |
20,463
+16,271
| +388% | +$804K | ﹤0.01% | 3858 |
|
|
2016
Q2 | $225K | Sell |
4,192
-22,393
| -84% | -$1.06M | ﹤0.01% | 5656 |
|
|
2016
Q1 | $1.19M | Buy |
26,585
+11,543
| +77% | +$468K | ﹤0.01% | 3261 |
|
|
2015
Q4 | $574K | Buy |
+15,042
| New | +$575K | ﹤0.01% | 4277 |
|
|
2015
Q2 | – | Sell |
-5,547
| Closed | -$198K | – | 8695 |
|
|
2015
Q1 | $228K | Sell |
5,547
-3,467
| -38% | -$140K | ﹤0.01% | 6019 |
|
|
2014
Q4 | $367K | Buy |
9,014
+8,758
| +3,421% | +$342K | ﹤0.01% | 5139 |
|
|
2014
Q3 | $9K | Sell |
256
-23,248
| -99% | -$1M | ﹤0.01% | 7775 |
|
|
2014
Q2 | $1.09M | Sell |
23,504
-347
| -1% | -$15.4K | ﹤0.01% | 3388 |
|
|
2014
Q1 | $981K | Buy |
23,851
+14,719
| +161% | +$547K | ﹤0.01% | 3451 |
|
|
2013
Q4 | $348K | Sell |
9,132
-4,585
| -33% | -$141K | ﹤0.01% | 4452 |
|
|
2013
Q3 | $328K | Buy |
13,717
+66
| +0.5% | +$1.48K | ﹤0.01% | 4259 |
|
|
2013
Q2 | $232K | Buy |
+13,651
| New | +$197K | ﹤0.01% | 4537 |
|
Other funds holding ANIK
CP
VCM
BFM
CM
Citadel Advisors's ANIK Position: Q1 2026 in Review
Citadel Advisors increased its Anika Therapeutics (ANIK) stake by 11% in Q1 2026, buying an estimated $58K and bringing the position to 52,062 shares worth $755K. The position accounts for ﹤0.01% of the portfolio, ranked #8340.
Citadel Advisors first reported a position in ANIK in Q2 2013 and has held it in 47 quarters since. The position peaked at $7.05M in Q3 2019. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.
- Citadel Advisors held 52,062 shares of Anika Therapeutics worth $755K as of Q1 2026.
- Citadel Advisors bought 4,996 Anika Therapeutics shares in Q1 2026, an estimated $58K.
- Anika Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8340 holding.
- Citadel Advisors first reported a position in Anika Therapeutics in Q2 2013 and has held it in 47 quarters since.
- Citadel Advisors's Anika Therapeutics position peaked at $7.05M in Q3 2019.
- 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.